Claris Bio

Claris Bio is a biotechnology startup leading the way in corneal therapy. Founded in 2018 and based in Jersey City, NJ, the company boasts a team of experienced biopharma industry executives and experts in ophthalmology. The company's foundational intellectual property is rooted in the groundbreaking work conducted at the Massachusetts Eye and Ear Infirmary by Dr. Reza Dana, MD, MSc, MPH, Claes Dohlman Chair in Ophthalmology, Harvard Medical School, and Dr. Sunil Chauhan, DVM, PhD, Principal Investigator and Associate Professor, Mass Eye and Ear, Harvard Medical School. Claris Bio's flagship program, the CSB-001 Ophthalmic Solution 0.1%, is a topical ocular biologic solution of oremepermin-α, aimed at restoring structural and functional corneal integrity in eyes with neurotrophic keratopathy (NK). The company recently secured a significant $57.00M Series A investment on 04 January 2024, with prominent investors including Novo Holdings, RA Capital Management, Janus Handerson, Mass General Brigham Ventures. For more information about Claris Bio, visit www.clarisbio.com.